Esophageal Tumor – Pipeline Review, H2 2012

Global Markets Direct’s, ''Esophageal Tumor - Pipeline Review, H2 2012'', provides an overview of the Esophageal Tumor therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Esophageal Tumor. ''Esophageal Tumor - Pipeline Review, H2 2012'' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Esophageal Tumor.
- A review of the Esophageal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Esophageal Tumor pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Esophageal Tumor.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Esophageal Tumor pipeline depth and focus of Esophageal Tumor therapeutics. 

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Esophageal Tumor Pipeline Review H2 2012

Published: July 2012                                                  No. of Pages: 28               

 Price: Single User:  US $ 500                                    Corporate User: 1500

 

Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Esophageal Tumor Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Esophageal Tumor 6
Esophageal Tumor Therapeutics under Development by Companies 8
Esophageal Tumor Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Esophageal Tumor Therapeutics – Products under Development by Companies 11
Esophageal Tumor Therapeutics – Products under Investigation by Universities/Institutes 12
Companies Involved in Esophageal Tumor Therapeutics Development 13
Proteo, Inc. 13
Esophageal Tumor – Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Drug Profiles 19
Elafin - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
HPPH - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Esophageal Tumor Therapeutics – Drug Profile Updates 23
Esophageal Tumor Therapeutics - Dormant Products 25
Esophageal Tumor – Product Development Milestones 26
Featured News & Press Releases 26
Aug 09, 2011: Tekmira Announces Additional Clinical Trial Of TKM-PLK1 With US National Cancer Institute 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28

List of Tables

List of Figures